Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2001-05-14
2003-02-25
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S278100, C424S283100, C514S025000
Reexamination Certificate
active
06524584
ABSTRACT:
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponi adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.
BRIEF DESCRIPTION OF THE BACKGROUND ART
Quillaja saponins are a mixture of triterpene glycosides extracted from the bark of the tree
Quillaja saponaria
. They have long been recognized as immune stimulators that can be used as vaccine adjuvants, (Campbell, J. B., and Peerbaye, Y. A.,
Res. Immunol.
143(5):526-530 (1992)), and a number of commercially available complex saponin extracts have been utilized as adjuvants. Crude saponins have been extensively employed as adjuvants in vaccines against foot and mouth disease, and in amplifying the protective immunity conferred by experimental vaccines against protozoal parasites such as
Trypanosoma cruzi
plasmodium and also the humoral response to sheep red blood cells (SRBC). (Bomford,
Int. Arch. Allerg. Appl. Immun.
67:127 (1982)).
The first commercially available Quillaja saponin adjuvants were crude extracts which, because of their variability, were not desirable for use in veterinary practice or in pharmaceutical compositions for man. An early attempt to purify Quillaja saponin adjuvants was made by Dalsgaard,
Archiv fuer die gesamte Virusforschung
44:243 (1974). Dalsgaard partially purified an aqueous extract of the saponin adjuvant material from
Quillaja saponaria
Molina. However, while Dalsgaard's preparation, “Quil-A,” was a definite improvement over the previously available commercial saponins, it still exhibited considerable heterogeneity.
Subsequent analysis via high-pressure liquid chromatography showed that Quil A was in fact a heterogeneous mixture of structurally related compounds. (U.S. Pat. No. 5,057,540; Kersten, G. F. A. et al.,
Infect. Immun.
56:432-438 (1988); Kensil, C. R. et al.,
J. Immunol.
146:431-437 (1991); Kensil, C. R. et al.,
J. Am. Vet. Med. Assoc.
199:1423-1427 (1991)). However, not all of these saponins were active as adjuvants.
The four most predominant purified Quillaja saponins are QS-7, QS-17, QS-18, and QS-21 (alternatively identified as QA-7, QA-17, QA-18, and QA-21). These saponins have been purified by HPLC and low pressure silica chromatography and were found to be adjuvant active, although differing in biological activities such as hemolysis and toxicity in mice. In particular, QS-21 and QS-7 were found to be least toxic in mice. (Kensil, C. R. et al.,
J. Immunol.
146:431-437 (1991)).
Due to its potent adjuvant activity and low toxicity, QS-21 (commercially available as the “Stimulon®” adjuvant) has been identified as a useful immunological adjuvant. (Kensil, C. R. et al., “Structural and Immunological Characterization of the Vaccine Adjuvant QS-21,” in
Vaccine Design: The Subunit and Adjuvant Approach
, Powell, M. F. and Newman, M. J. eds., Plenum Press, New York (1995)). QS-21 is a complex triterpene glycoside of quillaic acid. QS-21 is glycosylated at triterpene carbon 3, triterpene carbon 28, and carbon 5 of the second fatty acyl unit in a fatty acid domain.
More recently, QS-21 was further purified using hydrophilic interaction chromatography (HILIC) and resolved into two peaks, QS-21-V1 and QS-21-V2, which have been shown to be chemically different compounds. In C57b1/6 mice immunized with vaccines consisting of ovalbumin and either QS-21, QS-21-V1, or QS-21-V2, both of the individual components QS-21-V1 and QS-21-V2 are comparable in adjuvant effect to the original QS-21 peak (containing a mixture of 3:2 QS-21-V1 and QS-21-V2) for boosting the IgG subclasses IgG1, IgG2b, and IgG2 as well as the total IgG titer. (Co-pending U.S. patent application Ser. No. 07/906,880, now U.S. Pat. No. 5,583,112, the entire contents of which is hereby incorporated by reference).
Quillaja saponins are structurally distinct from the saponins derived from other plant species. Two structural features that distinguish
Quillaja saponaria
saponins from those of other plant species are a fatty acid domain and a triterpene aldehyde at carbon 4 of the triterpene. (Kensil, C. R. et al., “Structural and Immunological Characterization of the Vaccine Adjuvant QS-21, ” in
Vaccine Design: The Subunit and Adjuvant Approach
, Powell, M. F. and Newman, M. J. eds., Plenum Press, New York (1995)). Modifications to the aldehyde on the triterpene indicate that this functional group may be involved in the adjuvant mechanism (Soltysik, S. et al.,
Vaccine
13(15):1403-1410 (1995)).
Quillaja saponins, particularly QS-7, QS-17, QS-18, and QS-21, have been found to be excellent stimulators of antibody response to soluble T-dependent protein antigens, “subunit antigens”, which are poorly immunogenic and require a potent adjuvant for maximization of immune responses. Examples of purified subunit antigens for which saponin adjuvants will augment the IgG response in mice include keyhole limpet hemocyanin (KLH), HIV-1 gp120 (Bomford, R. et al,
AIDS Res. Hum. Retroviruses
8:1765 (1992)), and influenza nucleoprotein (Brett, S. et al.,
Immunology
80:306 (1993)). QS-7, QS-17, QS-18 and QS-21 have also been shown to stimulate potent antibody responses in mice to the antigens bovine serum albumin and cytochrome b
5
(Kensil, C. R. et al.,
J. Immunol.
146:431 (1991)). The level of antibody response induced by these purified saponins was comparable to other commonly used adjuvants, e.g., complete Freund's adjuvant, and superior to aluminum hydroxide.
QS-21 has also been shown to enhance antibody responses to T-independent antigens, including unconjugated bacterial polysaccharides (White, A. C. et al., “A purified saponin acts as an adjuvant for a T-independent antigen, in:
Immunobiology of Proteins and Peptides
, Vol. VI (M. Z. Atassi, ed.), Plenum Press, New York, pp. 207-210 (1991)). The immunogenicity of the vaccine was further increased by conjugating diphtheria toxoid to the polysaccharide. QS-21 enhanced the antibody response to the polysaccharide as well as the carrier, including IgG2a, IgG2b, and IgG3 responses. (Coughlin, R. T. et al.,
Vaccine
13(1):17-21 (1995)).
The ability of adjuvants to modulate the isotype distribution and IgG subclass distribution of antibody response to an antigen through the promotion of Ig subclass switching has important implications for immunity to many bacterial and viral vaccines. QS-7, QS-17, QS-18, and QS-21 stimulate IgG2a response to cytochrome b
5
after administration with saponin doses of 20 &mgr;g (Kensil, C. R. et al.,
J. Immunol
146:431 (1991)). In this regard, QS-21 shifts predominant IgG1 responses to a profile that includes significant IgG2b and IgG2a responses. For example, QS-21 has been shown to stimulate antigen-specific IgG2a to a number of antigens, including
Borrelia burgdorferi
outer surface proteins OspA and OspB (Ma, J. et al.,
Vaccine
12(10):925 (1994)), feline leukemia virus (FeLV), envelope gp70 (Kensil, C. R. et al.,
J. Am. Vet. Med. Assoc.
10:1423 (1991)), human cytomegalovirus (HCMV) envelope protein gB (Britt, W. etal.,
J. Infect. Dis.
171:18 (1995)), respiratory synctial virus (RSV) purified fusion protein (Hancock, G. E. et al.,
Vaccine
13(4):391 (1995)), and tetanus toxoid (Coughlin, R. T. et al.,
Vaccine
13(1):17 (1995)). QS-21 has also been shown to induce boostable antibody responses. (Britt et al.,
J. Infect. Dis.
171:18-25 (1995); Helling etal.,
Cancer Res.
55:2783-2788 (1995)).
The ability of the QS-21 adjuvant to induce class I major histocompatibility complex (MHC) antigen-restricted cytotoxic T-lymphocyte responses (CTL) after immunization with soluble proteins is a characteristic of saporin adjuvants. A number of studies have shown the ability of QS-21 to induce potent cytotoxic T-lymphocyte (CTL) responses to various ant
Antigenics Inc.
Pennie & Edmonds LLP
Saunders David
LandOfFree
Saponin compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Saponin compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Saponin compositions and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3144134